Immunotherapy and new combinations in muscle-invasive bladder cancer

Abstract

Muscle-invasive bladder cancer has been associated with a poor prognosis so far, despite the use of standard chemotherapy. The development of new anticancer immune compounds seems a very promising option for such disease both because of indisputable efficacy and good tolerance profile. This article reviews the evidence supporting such statement, according to the tumor stages and the type of innovative compounds. This chapter summarizes the published data, the ongoing trials and the regulatory approvals.